newsfilter
← Latest News
ClinicalTrials.gov·

SPEARHEAD-3 Pediatric Study - NCT05642455

Evaluate safety and tolerability of afamitresgene autoleucel and determination of an optimal tolerated dose range determined by incidence, severity and duration of Treatment Emergent Adverse Events and Incidence and DLTs as assessed by Investigator., Efficacy: Objective response rate (ORR) assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (or by International Neuroblastoma Response Criteria [INRC] 2017 in NB subjects), Time to response (TTR), (and 7 more...)